ReviewFrontiers in neurology2019
Cognitive Dysfunctions and Assessments in Multiple Sclerosis.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Comparing cognitive impairment using MACFIMS in patients with multiple sclerosis and healthy controls: a systematic review and meta-analysis.BMC neurology · 2024Pooled it
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Motor, cognitive, and combined rehabilitation approaches on MS patients' cognitive impairment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Trial
- A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- The Relationship between Cognitive Dysfunction and Postural Stability in Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2021Trial
- The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients.Nutrients · 2020Trial
- MicroRNA-mRNA Regulatory Network Associated with Cognitive Impairment in Multiple Sclerosis.Molecular neurobiology · 2026Article
- Age-Related Differences in Cognitive and Postural Performance During Dynamic Dual-Tasks.Sensors (Basel, Switzerland) · 2026Article
- Cognitive function is associated with risk of conversion to secondary progressive multiple sclerosis: A cross-sectional study.PloS one · 2026Article
- The Relationship Between Neurofilament Light Chain and B Lymphocyte Chemoattractant and Cognition in Multiple Sclerosis.Noro psikiyatri arsivi · 2026Article
- Norma Latina Neuropsychological Evaluation in Individuals with Multiple Sclerosis and Its Relationship with Disability.Brain sciences · 2025Article
- Biomarkers of Progression Independent of Relapse Activity-Can We Actually Measure It Yet?International journal of molecular sciences · 2025Review
- The influence of information processing speed on memory processes in patients with relapsing-remitting and primary progressive multiple sclerosis.Scientific reports · 2025Article
- Eye-Tracking Metrics as a Digital Biomarker for Neurocognitive Disorders in Multiple Sclerosis: A Scoping Review.Brain sciences · 2025Review
- Prevalence and Odds of Cognitive Impairment in Multiple Sclerosis Subtypes and Neuromyelitis Optica Spectrum Disorder: A Case-Control Study.Advanced biomedical research · 2025Article
- The effects of taekwondo on depression symptoms and cognitive function: a systematic review and meta-analysis.Frontiers in sports and active living · 2025Review
- Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.Journal of neurology · 2024Review
- A future of AI-driven personalized care for people with multiple sclerosis.Frontiers in immunology · 2024Article
- Article
- The relation between the symbol digit modalities test, fatigue, depression, and anxiety symptoms in a Belgian MS cohort.Acta neurologica Belgica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment has been reported at all phases and all subtypes of multiple sclerosis. It remains a major cause of neurological disability in young and middle-aged adults suffering from the disease. The severity and type of cognitive impairment varies considerably among individuals and can be observed both in early and in later stages. The areas which have commonly shown more deficits are: information processing speed, complex attention, memory, and executive function. Even though an alteration in both the white matter and in the gray matter has been found in patients with multiple sclerosis and cognitive impairment, the underlying process still remains unknown. Standardized neurological examinations fail to detect emerging cognitive deficits and self-reported cognitive complaints by the patients can be confounded by other subjective symptoms. This review is a comprehensive and short update of the literature on cognitive dysfunctions, the possible confounders and the impact of quality of life in patients with multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.